AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39352775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% via intercostal catheter
Number of subjects: 32
Study 39352861 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan
Number of subjects: 0
Study 39352861 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan and Dapagliflozin combination
Number of subjects: 0
Study 39352861 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39352862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulins (Igs) or monoclonal neutralizing antibodies as a therapeutic strategy
Number of subjects: 0
Study 39352862 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination to induce neutralizing antibodies
Number of subjects: 0
Study 39353092 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsular Tension Ring (CTR)
Number of subjects: 93
Study 39353092 — intervention group
Group type: COMPARATOR
Intervention: Non-Capsular Tension Ring (NCTR)
Number of subjects: 93
Study 39353160 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Epstein-Barr virus (EBV) viral capsid antigen/nuclear antigen 1-immunoglobulin A antibody tests in the screening group
Number of subjects: 361206
Study 39353160 — intervention group
Group type: COMPARATOR
Intervention: No intervention in the control group
Number of subjects: 361206
Study 39353163 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (100, 120, or 150 mg three times a week for 12 weeks)
Number of subjects: 159
Study 39353163 — intervention group
Group type: COMPARATOR
Intervention: rHuEPO-α (150 IU/kg three times a week for 12 weeks)
Number of subjects: 159
Study 39353163 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Roxadustat to rHuEPO-α
Number of subjects: 159
Study 39353163 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 159
Study 39353164 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple hysterectomy
Number of subjects: 0
Study 39353164 — intervention group
Group type: COMPARATOR
Intervention: Radical hysterectomy
Number of subjects: 0
Study 39353191 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Program (HEP) with a biopsychosocial approach, consisting of 5 educational sessions lasting between 90 and 120 minutes, carried out every other day.
Number of subjects: 0
Study 39353584 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale administered at baseline, 3 months, and 12 months post-inclusion
Number of subjects: 350
Study 39353584 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L administered at baseline, 3 months, and 12 months post-inclusion
Number of subjects: 350
Study 39353631 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (first dose)
Number of subjects: 0
Study 39353631 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination (second dose)
Number of subjects: 0
Study 39353631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tdap vaccination
Number of subjects: 0
Study 39353631 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 0
Study 39353677 — intervention group
Group type: EXPERIMENTAL
Intervention: DMEK plus topical placebo
Number of subjects: 60
Study 39353677 — intervention group
Group type: COMPARATOR
Intervention: DSO plus topical ripasudil 0.4%
Number of subjects: 60
Study 39353688 — intervention group
Group type: EXPERIMENTAL
Intervention: Genicular artery embolisation (GAE)
Number of subjects: 58
Study 39353688 — intervention group
Group type: COMPARATOR
Intervention: Sham GAE
Number of subjects: 58
Study 39353688 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 58
Study 39353688 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 58
Study 39353693 — intervention group
Group type: EXPERIMENTAL
Intervention: State-of-the-art tests for early detection of HCC
Number of subjects: 3000
Study 39353749 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab (700 mg)
Number of subjects: 84
Study 39353749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 39353749 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab
Number of subjects: 84
Study 39354195 — intervention group
Group type: EXPERIMENTAL
Intervention: CD5-gene-edited CAR-T cell therapy targeting CD5
Number of subjects: 19
Study 39354196 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 0
Study 39354196 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 39354341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (diet and exercise) over 12 months
Number of subjects: 176
Study 39354373 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 84
Study 39354373 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA
Number of subjects: 84
Study 39354373 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Mini-Cog score
Number of subjects: 84
Study 39354373 — intervention group
Group type: COMPARATOR
Intervention: Control group (negatively-screened Mini-Cog scores)
Number of subjects: 84
Study 39354453 — intervention group
Group type: EXPERIMENTAL
Intervention: Convoy-Pal intervention for patients
Number of subjects: 31
Study 39354453 — intervention group
Group type: EXPERIMENTAL
Intervention: Convoy-Pal intervention for caregivers
Number of subjects: 31
Study 39354453 — intervention group
Group type: COMPARATOR
Intervention: Control group for patients
Number of subjects: 31
Study 39354453 — intervention group
Group type: COMPARATOR
Intervention: Control group for caregivers
Number of subjects: 31
Study 39354472 — intervention group
Group type: EXPERIMENTAL
Intervention: I-TRANSFER-HF intervention (early and intensive HHC nurse visits combined with an early outpatient medical visit post-discharge)
Number of subjects: 0
Study 39354488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cancer screening delay
Number of subjects: 3790
Study 39354488 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 18 to 24 years
Number of subjects: 3790
Study 39354488 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 40 to 59 years
Number of subjects: 3790
Study 39354488 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group older than 60 years
Number of subjects: 3790
Study 39354488 — intervention group
Group type: EXPERIMENTAL
Intervention: Time on ART below 6 months
Number of subjects: 3790
Study 39354514 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme group training
Number of subjects: 728
Study 39354514 — intervention group
Group type: COMPARATOR
Intervention: Individual Otago Exercise Programme training
Number of subjects: 728
Study 39354514 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (both group and individual)
Number of subjects: 728
Study 39354514 — intervention group
Group type: EXPERIMENTAL
Intervention: Group format of Otago Exercise Programme
Number of subjects: 728
Study 39354514 — intervention group
Group type: COMPARATOR
Intervention: Individual training
Number of subjects: 728
Study 39354514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formats of Otago Exercise Programme
Number of subjects: 728
Study 39354536 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid simulation training
Number of subjects: 68
Study 39354536 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 68
Study 39354558 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian Cardioprotective diet supplemented with 30 g/day of mixed nuts (10 g of peanuts; 10 g of cashew; 10 g of Brazil nuts)
Number of subjects: 388
Study 39354558 — intervention group
Group type: COMPARATOR
Intervention: Only Brazilian Cardioprotective diet (DICA Br)
Number of subjects: 388
Study 39354558 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian Cardioprotective diet supplemented with 30 g/day of mixed nuts
Number of subjects: 388
Study 39354570 — intervention group
Group type: EXPERIMENTAL
Intervention: Vojta stimulation
Number of subjects: 120
Study 39354570 — intervention group
Group type: COMPARATOR
Intervention: MOTOMED
Number of subjects: 120
Study 39354572 — intervention group
Group type: EXPERIMENTAL
Intervention: School-Wide Positive Behavioral Interventions and Supports (SW-PBIS) program
Number of subjects: 0
Study 39354572 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 0
Study 39354572 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 39354611 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch vein grafts
Number of subjects: 1520
Study 39354611 — intervention group
Group type: COMPARATOR
Intervention: Conventional vein grafts
Number of subjects: 1520
Study 39354619 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dose ESWT (4000 pulses per session)
Number of subjects: 0
Study 39354619 — intervention group
Group type: COMPARATOR
Intervention: Control group (half the dose, 2000 pulses per session)
Number of subjects: 0
Study 39354625 — intervention group
Group type: EXPERIMENTAL
Intervention: JS007 (anti-CTLA-4 antibody) administered intravenously every 3 weeks at doses of 0.03, 0.3, 1, 3, and 10 mg/kg.
Number of subjects: 28
Study 39354625 — intervention group
Group type: EXPERIMENTAL
Intervention: JS007 (anti-CTLA-4 antibody) administered intravenously.
Number of subjects: 28
Study 39354985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 0
Study 39354985 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39355401 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMI)
Number of subjects: 37
Study 39355401 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU)
Number of subjects: 37
Study 39355401 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PTU and MMI
Number of subjects: 37
Study 39355572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 135
Study 39355572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 135
Study 39355572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.375% bupivacaine
Number of subjects: 135
Study 39355575 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio (CHR)
Number of subjects: 10917
Study 39355575 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 10917
Study 39355649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran treatment
Number of subjects: 18
Study 39355793 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged 120-h meropenem antibiotic prophylaxis (Group B)
Number of subjects: 92
Study 39355793 — intervention group
Group type: COMPARATOR
Intervention: Standard 24-h antibiotic prophylaxis (Group A)
Number of subjects: 92
Study 39355924 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonist treatment in patients with PA
Number of subjects: 80
Study 39355924 — intervention group
Group type: COMPARATOR
Intervention: Normotensive controls
Number of subjects: 80
Study 39355924 — intervention group
Group type: COMPARATOR
Intervention: Essential hypertensives
Number of subjects: 80
Study 39356039 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan (V2R antagonist)
Number of subjects: 8016
Study 39356039 — intervention group
Group type: COMPARATOR
Intervention: Various pharmacological interventions (including antihypertensive therapy, mTOR inhibitors, somatostatin analogues, etc.)
Number of subjects: 8016
Study 39356039 — intervention group
Group type: COMPARATOR
Intervention: Tolvaptan
Number of subjects: 8016
Study 39356043 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam (BRV) treatment, median dose 1.0 mg/kg/day (range 0.4-7.5 mg/kg/day)
Number of subjects: 209
Study 39356050 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV (Bilevel Positive Airway Pressure - BiPAP)
Number of subjects: 120
Study 39356050 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 120
Study 39356138 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (2.5 mg/kg i.v., every week × 13), paclitaxel (80 mg/m2 i.v. every week × 12), and carboplatin (AUC = 4 i.v., every 3 weeks × 4)
Number of subjects: 43
Study 39356138 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab, carboplatin, and paclitaxel
Number of subjects: 43
Study 39356507 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium aspartate, 10 to 15 mg/d for 3 weeks
Number of subjects: 52
Study 39356507 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label lithium aspartate, 40 to 45 mg/d for 6 weeks (in dose-finding study)
Number of subjects: 52
Study 39356507 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 52
Study 39356530 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVM (splanchnic nerve ablation)
Number of subjects: 90
Study 39356530 — intervention group
Group type: COMPARATOR
Intervention: Sham control procedure
Number of subjects: 90
Study 39356530 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVM
Number of subjects: 90
Study 39356530 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 90
Study 39356537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA) - loading dose of 10 mg/kg followed by maintenance infusion of 5 mg/kg per hour during surgery
Number of subjects: 353
Study 39356537 — intervention group
Group type: COMPARATOR
Intervention: Placebo - indistinguishable matching placebo
Number of subjects: 353
Study 39356537 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 353
Study 39356537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study 39356541 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning Through Play Plus Dads (LTP + Dads) intervention
Number of subjects: 357
Study 39356541 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 357
Study 39356542 — intervention group
Group type: COMPARATOR
Intervention: ICD
Number of subjects: 323
Study 39356542 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 323
Study 39356943 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior rectal artery embolization
Number of subjects: 15
Study 39356946 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Number of subjects: 50
Study 39356946 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Ethanol Injection
Number of subjects: 50
Study 39356946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 50
Study 39356963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis patients
Number of subjects: 113
Study 39356963 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 113
Study 39357046 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-based digital intervention
Number of subjects: 80
Study 39357046 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 80
Study 39357051 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing at Home (MAH) serious game intervention
Number of subjects: 500
Study 39357056 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-azacitidine in ex vivo sensitive participants
Number of subjects: 104
Study 39357056 — intervention group
Group type: COMPARATOR
Intervention: Ex vivo resistant patients
Number of subjects: 104
Study 39357104 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect-based menu
Number of subjects: 0
Study 39357104 — intervention group
Group type: COMPARATOR
Intervention: Plant-based menu
Number of subjects: 0
Study 39357645 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary microvascular vasodilator capacity
Number of subjects: 0
Study 39357645 — intervention group
Group type: EXPERIMENTAL
Intervention: Prominent dicrotic notch
Number of subjects: 0
Study 39357645 — intervention group
Group type: EXPERIMENTAL
Intervention: Better microcirculatory health
Number of subjects: 0
Study 39357673 — intervention group
Group type: EXPERIMENTAL
Intervention: Beans (120 g, ∼0.75 cups)
Number of subjects: 180
Study 39357673 — intervention group
Group type: EXPERIMENTAL
Intervention: Peas (120 g, ∼0.75 cups)
Number of subjects: 180
Study 39357673 — intervention group
Group type: COMPARATOR
Intervention: Control (Rice)
Number of subjects: 180
Study 39357788 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 437
Study 39357788 — intervention group
Group type: COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 437
Study 39357863 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D vision system
Number of subjects: 54
Study 39357863 — intervention group
Group type: COMPARATOR
Intervention: 4K vision system
Number of subjects: 54
Study 39357888 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device (PED) Classic and Flex
Number of subjects: 133
Study 39357896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial tenecteplase
Number of subjects: 256
Study 39357896 — intervention group
Group type: COMPARATOR
Intervention: Best medical management
Number of subjects: 256
Study 39357988 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory viral testing (for RSV, influenza, and SARS-CoV-2)
Number of subjects: 1821
Study 39357988 — intervention group
Group type: COMPARATOR
Intervention: Negative respiratory viral test
Number of subjects: 1821
Study 39357988 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive respiratory viral test in infants aged 29 days and older
Number of subjects: 1821
Study 39357994 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning algorithm for detecting inflammation on MRI of sacroiliac joints (SIJ)
Number of subjects: 731
Study 39357994 — intervention group
Group type: COMPARATOR
Intervention: Human central readings for detecting inflammation on MRI of sacroiliac joints (SIJ)
Number of subjects: 731
Study 39358039 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention
Number of subjects: 363
Study 39358039 — intervention group
Group type: COMPARATOR
Intervention: Later intervention
Number of subjects: 363
Study 39358106 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegan Mediterranean diet
Number of subjects: 14
Study 39358206 — intervention group
Group type: EXPERIMENTAL
Intervention: Zagreb 2-1-1 regimen
Number of subjects: 240
Study 39358206 — intervention group
Group type: COMPARATOR
Intervention: Essen 5 regimen
Number of subjects: 240
Study 39358355 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg davunetide/daily
Number of subjects: 144
Study 39358355 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg davunetide/twice-daily
Number of subjects: 144
Study 39358355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 39358661 — intervention group
Group type: EXPERIMENTAL
Intervention: Selvigaltin (GB1211) 100 mg oral
Number of subjects: 12
Study 39358661 — intervention group
Group type: COMPARATOR
Intervention: Healthy-matched participants (control)
Number of subjects: 12
Study 39358667 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg risankizumab
Number of subjects: 897
Study 39358699 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity monitoring with motivational feedback via a patient app for 12 weeks
Number of subjects: 150
Study 39358699 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (activity monitoring without motivational feedback)
Number of subjects: 150
Study 39358750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh-augmented sacrospinal fixation with anterior and posterior colporrhaphy without perineoplasty
Number of subjects: 310
Study 39358750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh-augmented sacrospinal fixation with anterior and posterior colporrhaphy and perineoplasty
Number of subjects: 310
Study 39358759 — intervention group
Group type: EXPERIMENTAL
Intervention: Municipality-based intervention for breastfeeding support
Number of subjects: 0
Study 39358761 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-binomial regression model
Number of subjects: 0
Study 39358761 — intervention group
Group type: EXPERIMENTAL
Intervention: Untransformed MLR
Number of subjects: 0
Study 39358761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobit regression
Number of subjects: 0
Study 39358761 — intervention group
Group type: EXPERIMENTAL
Intervention: MLR with square root and log transformations
Number of subjects: 0
Study 39358761 — intervention group
Group type: COMPARATOR
Intervention: Untransformed MLR, beta-binomial, and Tobit
Number of subjects: 0
Study 39358806 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (EQW) 2 mg once weekly
Number of subjects: 3973
Study 39358806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3973
Study 39359014 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg twice daily for 3 months
Number of subjects: 88
Study 39359014 — intervention group
Group type: COMPARATOR
Intervention: Guideline-directed medical therapy for STEMI
Number of subjects: 88
Study 39359154 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Mental Health Program (PMHP)
Number of subjects: 0
Study 39359154 — intervention group
Group type: COMPARATOR
Intervention: Standby control group
Number of subjects: 0
Study 39359164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure (SBP) lowering aiming for < 120 mmHg
Number of subjects: 234
Study 39359164 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure (SBP) goal of < 140 mmHg
Number of subjects: 234
Study 39359613 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Diaphragm Release Technique (MDRT) in conjunction with Breathing Retraining Exercises (BRE)
Number of subjects: 24
Study 39359613 — intervention group
Group type: COMPARATOR
Intervention: Breathing Retraining Exercises (BRE)
Number of subjects: 24
Study 39359872 — intervention group
Group type: COMPARATOR
Intervention: Physical facial nerve rehabilitation (PFNR) therapy alone (neuromuscular retraining and Kabat proprioceptive neuromuscular facilitation)
Number of subjects: 25
Study 39359872 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical facial nerve rehabilitation (PFNR) with early eyelid surgery (90 days after FP onset)
Number of subjects: 25
Study 39360368 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,200 mg/day orally
Number of subjects: 60